Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10363588 | 1.00 | RAB9A (0.39) | RAB9APRCPTLR2DPP7DPP4 | |
| SCHEMBL5539757 | 0.95 | RAB9A (0.38) | RAB9APRCPTLR2TSHRCYP1A2 | |
| SCHEMBL8840314 | 0.89 | PRCP (0.39) | PRCPTLR2DPP7DPP4DPP8 | |
| SCHEMBL17732291 | 0.88 | PRCP (0.38) | PRCPTLR2DPP7DPP4DPP8 | |
| SCHEMBL1263537 | 0.86 | TLR2 (0.35) | PRCPTLR2DPP7DPP4DPP8 | |
| SCHEMBL11253690 | 0.84 | TLR2 (0.36) | PRCPTLR2DPP7DPP4DPP8 | |
| SCHEMBL13728121 | 0.83 | ADRB2 (0.36) | PRCPTLR2TSHRCYP3A4CYP2D6 | |
| SCHEMBL29520055 | 0.83 | GLI1 (0.47) | RAB9ATSHR | |
| SCHEMBL24587253 | 0.81 | TLR2 (0.40) | PRCPTLR2DPP7DPP4DPP8 | |
| SCHEMBL27114716 | 0.81 | TLR2 (0.40) | PRCPTLR2DPP7DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0053017-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-02-20 | — | — | EP | claimed |
| CN-117412959-A | Substituted 1-aryl-1 '-heteroaryl compounds, substituted 1,1' -biaryl compounds, and methods of use thereof | 爱彼特生物制药公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-2928503-B1 | CONJUGATES OF AURISTATIN COMPOUNDS | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-8614205-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-06-13 | — | — | US | disclosed |
| US-8258118-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-04 | — | — | US | disclosed |
| US-8211882-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120114643-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-8124768-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124768-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| WO-2010101648-A1 | GLUTAMATE RECEPTOR MODULATORS AND THERAPEUTIC AGENTS | WOOD RICHARD D (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | disclosed |
| EP-0241094-B1 | PROCESS FOR THE SEPARATION OF L-LEUCINE AND L-ISOLEUCINE | PFW (NEDERLAND) B.V. (NL) | 1990-07-25 | — | — | EP | disclosed |
| EP-0241094-A1 | Process for the separation of L-leucine and L-isoleucine | PFW (NEDERLAND) B.V. (NL) | 1987-10-14 | — | — | EP | disclosed |
| EP-0053017-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | RAB9A 2312/4885PRCP 3922/4885TLR2 314/4885 |
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | DPYD, CDK4, G6PD | RAB9A 1324/4885PRCP 2376/4885TLR2 4315/4885 |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | RAB9A 2147/4885PRCP 3421/4885TLR2 336/4885 |
| US-20120114643-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | DPYD, CDK4, G6PD | RAB9A 1324/4885PRCP 2376/4885TLR2 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.